About Avita Medical
Avita Medical (ASX:AVH) is a medical technology company that develops and commercialises regenerative medicine products for the treatment of chronic wounds. The company's flagship product is ReCell®, an autologous skin cell therapy that uses a patient's own skin cells to create a spray-on skin that is used to treat a variety of chronic wounds, including burns, diabetic ulcers, and pressure sores. Avita Medical is currently working on a number of projects, including the development of new ReCell® indications, the expansion of its global sales and marketing reach, and the development of new regenerative medicine products. Avita Medical's objectives are to become the leading provider of regenerative medicine products for the treatment of chronic wounds and to improve the lives of patients with chronic wounds.
Snapshot
Operations
Products and/or services of Avita Medical
- ReCell® autologous skin cell therapy: ReCell® is a spray-on skin therapy that uses a patient's own skin cells to treat a variety of chronic wounds, including burns, diabetic ulcers, and pressure sores.
- ReCell® for burns: ReCell® is approved by the FDA for the treatment of acute thermal burns in adult patients.
- ReCell® for chronic wounds: ReCell® is approved by the FDA for the treatment of full-thickness skin defects, including diabetic ulcers and pressure sores.
- ReCell® for vitiligo: ReCell® is being investigated for the treatment of vitiligo, a chronic skin condition that causes depigmentation of the skin.
- Rejuvenation: Avita Medical is exploring novel RNA-based approaches for rejuvenation.
- Research and development: Avita Medical is committed to research and development, with a focus on developing new and innovative regenerative medicine products.
Avita Medical executive team
- Mr. Cary G. VanceIndependent Non-Executive Chairman & Interim CEO
- Mr. David O'TooleChief Financial Officer
- Ms. Nicole Linda KelseyChief Legal & Compliance Officer and Corporate Secretary
- David MelbyeSenior Vice President of Operations
- Dr. Katie Bush Ph.D.Senior Vice President of Scientific & Medical Affairs
- Mr. Ben AtkinsVice President of Investor Relations & Corporate Communications
- Ms. Debbie GarnerSenior Vice President of Global Marketing & Strategy
- Dr. Niraj Doshi J.D., P.M.P., Ph.D.Senior VP of R&D, Program Management and Business Development
- Mr. Ron LagerquistSenior Vice President of Quality Assurance & Regulatory Affairs
- Ms. Robin VanDenburghSenior Vice President of U.S. Commercial Sales